Trials / Completed
CompletedNCT00071136
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 48 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pemetrexed | |
| DRUG | gemcitabine |
Timeline
- Start date
- 2003-12-01
- Completion
- 2006-08-01
- First posted
- 2003-10-16
- Last updated
- 2007-01-26
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00071136. Inclusion in this directory is not an endorsement.